Injectafer (ferric carboxymaltose injection) receives FDA approval for the treatment of paediatric patients with iron deficiency anaemia

Daiichi Sankyo

15 December 2021 - For patients as young as one year of age who have intolerance to, or have had an unsatisfactory response to, oral iron, Injectafer may now be administered for iron deficiency anaemia treatment.

Daiichi Sankyo and American Regent today announced that the U.S. FDA has approved Injectafer for paediatric patients (who are 1 year of age or older) with iron deficiency anaemia who are intolerant to oral iron or who have had an unsatisfactory response to oral iron.

Read Daiichi Sankyo press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US , Paediatrics